Who
Behzad Aghazadeh
Director and 10% owner and Other role
Company insider
Files Form 4 as: Director and 10% owner and Other, Scribe Therapeutics; Director and 10% owner and Other, Whitehawk Therapeutics; 10% owner, CymaBay Therapeutics; Director, Immunomedics; 10% owner, Mirati Therapeutics.
In numbers
- Trades disclosed
- 47
- Buys
- 8
- Sells
- 5
- Bought
- $164.3M
- Sold
- $75.1M
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 24 Aug 2017
- Last trade
- 28 Jul 2026
- Last filed
- 28 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Jul 2026filed 28 Jul 2026 | SCTX Scribe TherapeuticsBiotechnology | SEC FORM 4 Bought | $144K7,905 at $18.25 | filing |
| 24 Jul 2026filed 28 Jul 2026 | SCTX Scribe TherapeuticsBiotechnology | SEC FORM 4 Bought | $35.0M2,333,333 at $15.00 | filing |
| 24 Jul 2026filed 28 Jul 2026 | SCTX Scribe TherapeuticsBiotechnology | SEC FORM 4 Bought | $1.1M50,000 at $22.31 | filing |
| 23 Jul 2026filed 27 Jul 2026 | SCTX Scribe Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,725 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | WHWK Whitehawk Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,040 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | WHWK Whitehawk Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,040 at $0.00 | filing |
| 28 Feb 2025filed 4 Mar 2025 | WHWK Whitehawk Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $20.0M8,333,000 at $2.40 | filing |
| 13 Sep 2023filed 14 Sep 2023 | CymaBay Therapeuticsoption or derivative | SEC FORM 4 Code S | $245250 at $0.98 | filing |
| 13 Sep 2023filed 14 Sep 2023 | CymaBay Therapeuticsoption or derivative | SEC FORM 4 Code S | $1,045950 at $1.10 | filing |
| 12 Sep 2023filed 14 Sep 2023 | CymaBay Therapeuticsoption or derivative | SEC FORM 4 Code S | $1,5001,500 at $1.00 | filing |
| 12 Sep 2023filed 14 Sep 2023 | CymaBay Therapeuticsoption or derivative | SEC FORM 4 Code S | $300300 at $1.00 | filing |
| 12 Sep 2023filed 14 Sep 2023 | CymaBay Therapeuticsoption or derivative | SEC FORM 4 Code P | $10.0M583,771 at $17.13 | filing |
| 15 Jun 2023filed 20 Jun 2023 | WHWK Whitehawk Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,255 at $0.00 | filing |
| 26 Jan 2023filed 30 Jan 2023 | CymaBay Therapeuticsoption or derivative | SEC FORM 4 Code P | $15.0M2,142,857 at $7.00 | filing |
| 22 Nov 2021filed 23 Nov 2021 | CymaBay Therapeuticsoption or derivative | SEC FORM 4 Code P | $10.0M2,500,000 at $4.00 | filing |
| 27 Aug 2021filed 30 Aug 2021 | WHWK Whitehawk Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,549 at $0.00 | filing |
| 26 Aug 2021filed 30 Aug 2021 | WHWK Whitehawk TherapeuticsBiotechnology | SEC FORM 4 Code A | $25.0M1,911,752 at $13.08 | filing |
| 23 Oct 2020filed 23 Oct 2020 | Immunomedicsoption or derivative | SEC FORM 4 Code D | —202,614 | filing |
| 23 Oct 2020filed 23 Oct 2020 | Immunomedicsoption or derivative | SEC FORM 4 Code D | —103,718 | filing |
| 23 Oct 2020filed 23 Oct 2020 | Immunomedics | SEC FORM 4 Code D | —13,516 | filing |
News
No headline names them, or the companies they trade most, lately.